Skip to content
OpenCapital
Get started

Amgen AMGN Repatha — Total revenues

Other product segments

Other products
$1.53B+3.6%
Prolia
$727M-33.8%
EVENITY
$562M+27.1%
TEPEZZA
$490M+28.6%
Otezla
$431M-1.4%
BLINCYTO
$415M+12.2%
Nplate
$412M+31.6%
XGEVA
$411M-27.4%
TEZSPIRE
$343M+20.4%
KYPROLIS
$330M+1.9%
ENBREL
$320M-37.3%
Aranesp
$311M-8.5%
Vectibix
$287M+7.5%
UPLIZNA
$262M+188%
IMDELLTRA/IMDYLLTRA
$258M+219%
KRYSTEXXA
$255M+8.1%

Similar metrics at other companies

RFL
RFLProduct Revenue — Revenue
$89K-63.4%
Veracyte logo
VCYTBiopharmaceutical revenue — Total Revenue
$301K-86.9%
Cumberland Pharmaceuticals logo
CPIXProduct — Revenue
$10.1M+10.6%
ESP
ESPRProduct sales, net — Total Revenues
$43.4M+24.3%
Incyte logo
INCYTABRECTA — Total revenues
$6.7M+1.5%
Rhythm Pharmaceuticals, Inc. logo
RYTMProduct revenue, net — Total revenues
$60.11M+59.4%

Other financials

Income statement

See full
Revenue$8.6B+5.8%
Gross profit$5.9B+13.4%
Operating income$2.7B+126%
Net income$1.8B+5.1%
EPS (diluted)$3.34+4.4%

Balance sheet

See full
Cash & equivalents$559.0M+10.0%
Total debt$57.3B-0.1%
Total equity$9.2B+48.1%
Total assets$92.5B+3.5%

Cash flow

See full
Operating cash flow$2.2B+57.4%
CapEx$712.0M+73.2%
Free cash flow$1.5B+50.7%

Valuation

See full
Market cap$212.16B+30.0%
Enterprise value$268.92B+22.9%
P/E27.2×+2.5×
P/S5.7×+1.0×

Profitability

See full
Gross margin68.3%+5.3pp
Operating margin28.4%+6.6pp
Net margin21%+3.6pp
FCF margin23.1%-8.9pp

Returns & leverage

See full
Return on equity101.3%-4.4pp
Debt / equity6.2×-3.0×
Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Amgen’s 10-K, filed February 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's repatha — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amgen's repatha — total revenues?
Amgen (AMGN) reported repatha — total revenues of $754M in Q4 2025.
How has Amgen's repatha — total revenues changed year-over-year?
Amgen's repatha — total revenues increased by 35.7% year-over-year, from $555.5M to $754M.
What is the long-term trend for Amgen's repatha — total revenues?
Over 2 years (2023 to 2025), Amgen's repatha — total revenues has grown at a 35.8% compound annual growth rate (CAGR), from $1.64B to $3.02B.
What does repatha — total revenues mean?
This metric represents the total gross revenue generated from the global sales of a specific biologic therapeutic product within the cardiovascular portfolio. It reflects the market adoption, pricing strategy, and volume of prescriptions for this specific class of cholesterol-lowering medication. Tracking this revenue stream is essential for evaluating the commercial success and growth trajectory of the company's cardiovascular franchise.